S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
AVROBIO, Inc. (AVRO)
Chart Events
Performance Outlook
| Previous Close | 0.7710 |
| Open | 0.8048 |
| Bid | 0.7575 x 3000 |
| Ask | 0.8200 x 1200 |
| Day's Range | 0.7617 - 0.8460 |
| 52 Week Range | 0.7400 - 11.0000 |
| Volume | |
| Avg. Volume | 404,743 |
| Market Cap | 34.529M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8620 |
| Earnings Date | Mar 16, 2022 - Mar 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.86 |
- Zacks
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.
- Benzinga
Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study
Avrobio Inc (NASDAQ: AVRO) announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in infantile-onset Pompe disease. Pompe disease is a lysosomal disorder caused by a mutation in the GAA gene. The lack of the enzyme encoded by GAA results in a toxic buildup of glycogen throughout the body and central nervous system. The results demonstrate that gene therapy using hematopoietic stem cells (HSC) significantly reduced the toxic accumulation of glycogen in a mouse
- Business Wire
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
CAMBRIDGE, Mass., May 18, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. The results, which will be presented today during the "Disease models and Clinical Applications: Musculo-skeletal Diseases" poster session at the American Society of Gene
